(AFX UK Focus) 2009-06-02 19:37 UPDATE 2-US FDA aims to make its decisions more transparent (Interactive Investor)
By Lisa Richwine

FDA Advisory Panel Makes Favorable Recommendation For GlaxoSmithKline And Genmab's ARZERRA(TM) (ofatumumab) (Medical News Today)
GlaxoSmithKline [NYSE: GSK] and Genmab A/S [OMX: GEN] announced that the United States Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 10 to three that the ARZERRA(TM) (ofatumumab) data are reasonably likely to predict clinical benefit for patients with chronic lymphocytic leukemia (CLL) whose disease is refractory to fludarabine and alemtuzumab.